Institute for Bioscience and Biotechnology Research Receives $16.8 M Investment from the National Institute of Standards and Technology

Institute for Bioscience and Biotechnology Research | January 14, 2022

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges.

IBBR is a joint research enterprise of the University of Maryland, College Park, the University of Maryland, Baltimore and NIST. Research born out of this new cooperative agreement will be applied to accelerating the development and manufacturing of new pharmaceutical and vaccine approaches including cell and gene therapies and mRNA vaccines. This type of bioscience and bioengineering research will enable robust and rapid responses to pandemics and help remove obstacles to care and treatment related to rare childhood diseases and complex cancers.

"Trusting in and funding research makes it possible to find solutions to address major health and scientific challenges, and to prepare for the unknown. UMB has invested heavily in operational support and high-end instruments for IBBR in support of the NIST relationship. I am very pleased to see that the long-standing NIST collaboration will continue."

 Bruce E. Jarrell, MD, FACS, President of the University of Maryland, Baltimore

As part of the new agreement, NIST provided state-of-the-art equipment for the "IBBR Commons"—a highly sophisticated research space shared with researchers throughout Maryland and the nation. For example, NIST recently partnered with Maryland to establish the Maryland Center for Advanced Molecular Analysis (M-CAMA) that established new cryo-electron (cryoEM) instruments and facilities to be used by NIST and researchers in Maryland for the timely development of new therapies and vaccines.

"IBBR has long provided the critical link necessary to bring together researchers across disciplines to address major health challenges and help strengthen the state's economic base in bioscience and biotechnology," said Darryll J. Pines, Ph.D., President of the University of Maryland, College Park. "I am so pleased this collaboration between NIST and the University of Maryland, Baltimore and the University of Maryland, College Park remains strong, and I look forward to seeing the innovations it will lead to in the future."

IBBR was established by the University System of Maryland Board of Regents in 2010, building on and integrating previous partnerships between the University of Maryland and NIST that date back to 1984. The institute connects dozens of experts from interrelated fields of study with the common goal of accomplishing world-class interdisciplinary research that can lead to real-world advances like drug discovery, more effective vaccines, and disease prevention and treatment.

"Achieving truly groundbreaking results in fields like bioscience and biotechnology requires a wide array of resources, perspectives and expertise—from pharmaceutical and biotech companies to academic and government institutions, to foundations and NGOs," said Jennifer King Rice, Ph.D., Senior Vice President and Provost of the University of Maryland, College Park. "What makes IBBR so unique and impactful is its ability to stand in the center of this circle of voices as the catalyst for collaborative and impactful work."

"Having this important cooperative agreement with NIST enables us to develop and share the most sophisticated and advanced instrumentation for use in the discovery, development and manufacturing of safe and effective new medicines to treat human disease—including, most recently, for COVID19," said E. Albert Reece, MD, Ph.D., MBA, Executive Vice President for Medical Affairs at the University of Maryland, Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine.

About IBBR
IBBR is a joint research enterprise of the University of Maryland, College Park, the University of Maryland, Baltimore, and the National Institute of Standards and Technology. IBBR brings together critical elements necessary to inspire transformative discoveries in the field of bioscience and biotechnology and provides innovative solutions to major scientific and engineering challenges important to society. IBBR researchers seek to advance the fields of biomedical research, therapeutic development, biomedical manufacturing, and state-of-the-art measurement technologies, to support accelerated delivery of safe and effective medicines to the public. IBBR is financially supported in part by the University of Maryland Strategic Partnership: MPowering the State, an initiative designed to achieve innovation and impact through collaboration.


The scope of the journal includes the research, industrial and commercial aspects of biotechnology, in areas such as: Healthcare and Pharmaceuticals; Food and Agriculture; Biofuels; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Nanotechnology; Environment and Biodiversity; Biocatalysis; Bioremediation; Process engineering.

Other News

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. “This clinical trial in Brazil is the second international study to get under way in our efforts to help partners in historically underserved nations fight this pandemic by transferring our unique technology to provide them local control over development, manufacturing and distribution of a COVID-19 RNA vaccine. The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase 2 and Phase 3 trials.” HDT Bio CEO Steve Reed HDT Bio has other partnerships for its RNA COVID-19 vaccine, including in South Korea and China. “These partnerships are part of our company’s mission and business strategy aimed at bringing our advanced immunotherapies to underserved nations to help address global health inequities,” Reed explained. "Through the partnership with HDT Bio Corp., SENAI CIMATEC is incorporating in Brazil the development and qualification for a state-of-the-art technology in an exclusive way, as well as the first clinical study involving an RNA self-amplifying vaccine. This moment can be considered as an important demonstration of the potential of Brazilian science, represented in this study by SENAI CIMATEC,” said President of Federation of Industries of the State of Bahia Ricardo Alban “We also highlight the important funding received through the Ministry of Science, Technology and Innovations which has supported the execution of the initial clinical phases, “Alban added. “From the clinical studies of the Vaccine RNA MCTI CIMATEC HDT we expect to obtain sufficient data to demonstrate the efficacy and safety of this product to the population. In this way, the development of the Vaccine RNA MCTI CIMATEC HDT represents a crucial milestone for the modernization of the national health system, since it can later be produced in the country itself,” said infectious disease doctor and Principal Investigator of the clinical studies in Brazil Roberto Badaró. SENAI CIMATEC’s double-blind, placebo-controlled, dose-ranging Phase 1 clinical trial will enroll 90 healthy adult volunteers. The trial will assess the safety, tolerability, and immunogenicity of the vaccine at three dose levels, 1 µg, 5 µg and 25 µg. Safety and tolerability will be the primary endpoints assessed by incidence of adverse events for each dose through 12 months after the vaccination. Scheduled interim evaluations to measure immunogenicity also will be conducted. HDT Bio’s innovative vaccine, which also will undergo a Phase 1 trial in the U.S., uses its proprietary lipid nanoparticle carrier system for delivery of RNA. The vaccine is significantly different from existing commercially available RNA vaccines in two ways. First, its RNA payload is designed to amplify itself inside the body. As a result, the vaccine activates the immune system at a much lower dose than commercially available vaccines, enhancing safety and reducing manufacturing costs. Second, the RNA attaches to the outside of the nanoparticle delivery system rather than being encapsulated within it, providing for enhanced stability. ABOUT HDT BIO CORP. HDT Bio is a biopharmaceutical company dedicated to providing immunotherapies to people around the world, including those in historically underserved areas. The company seeks to harness the body’s immune system to deliver therapies that narrowly target the specific areas of the body where they are needed. HDT Bio’s work focuses on oncological and infectious disease applications. HDT Bio’s founders are world leaders in the development of immune stimulants, including both therapeutics and therapy-enhancing adjuvants. One of the company’s core technologies, RNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination. ABOUT SENAI CIMATEC SENAI CIMATEC focuses on higher education, research and innovation for the development of industry. Its manufacturing and technology integrated campus is one of the most advanced centers for education specialized services, applied research and innovation projects in Brazil. CIMATEC operates in more than 40 different areas of competence, with emphasis on computer technology, engineering, health and biotechnology, with the main objective to support industries, including the Brazilian Industrial Health Complex.

Read More


Cardea Bio completes planned launch of CRISPR QC

Cardea Bio | April 06, 2022

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establishing dedicated lab facilities and office spaces, as well as completing the initial investor funding, CRISPR QC is now ready to offer analysis services for R&D groups in therapeutics, animal breeding, plant biology, and academics in need of advanced insights to their CRISPR efforts. One of the challenges for successful CRISPR gene editing is a lack of understanding and standardization of processes around predicting and optimizing CRISPR assay outcomes. At CRISPR QC, we work with scientists to improve the quality of life for all. That's why we're excited to work with the Chief Scientific Officer of Cardea Bio, Dr. Kiana Aran, who recently received NIH funding to help set some of the US quality control standards for CRISPR therapies, In addition to this, CRISPR QC provides previously unavailable data and insight into the CRISPR editing process, resulting in significant time-savings and first to market application opportunities for our customers, including CRISPR/Cas technology-driven solutions which are commercially available as of now." Ross Bundy, President of CRISPR QC. With CRISPR QC going into business with valuable first-of-a-kind services in the growing CRISPR space, we can now showcase a distinct example of what our BPU Platform can enable our partners to do - products and applications otherwise not possible. That in turn drives growth opportunities and revenue for Cardea Bio, unlocking significant value for both CRISPR QC's and Cardea's stakeholders, I'm anticipating that CRISPR QC will get a number of near-term opportunities to help its customers bring transformative gene-editing insights and solutions to scientists and researchers working on CRISPR therapies, as well as other market changing applications." Michael Heltzen, CEO at Cardea Bio. About CRISPR QC Inc. CRISPR QC is a biotechnology company dedicated to improving the capabilities of scientists and researchers to improve their CRISPR assay designs through technological innovation. Using market-leading solutions, we can identify CRISPR activity in amplicons and genomic DNA and model results of the CRISPR process In vivo vs. In vitro. Our service is available to therapeutic companies and academic researchers to help them accelerate the development of their CRISPR-based therapies and to animal breeding and plant biology scientists who seek to improve the food chain for humankind. About Cardea Bio Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health.

Read More


Portal Innovations Expands Chicago Operations Triples Space in Fulton Labs

Portal Innovations | February 03, 2022

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 years of experience building high-performing teams and collaborations with corporate partners in several public and private life sciences companies, Patrick brings his seasoned biotech-entrepreneurial experience to navigate Portal’s portfolio expansion. Patrick was the founding Executive Director at MATTER and currently serves as a Managing Director at Portal. “I am excited to partner with Patrick as we continue to build Portal into a premier platform of investment in transformative companies with the best innovators, entrepreneurs, academic institutions, and venture capitalists. Patrick’s experience and vision are crucial for Portal to reach the next level here in Chicago.” Portal Founder and CEO John Flavin Through its “Crafted Capital” model, Portal invests seed financial funding, offers access to fully equipped wet and dry lab space, and provides management expertise to leading scientific and entrepreneurial founders. Portal is building a valuable portfolio of life sciences companies at the seed to series A investment stage for long-term value creation. Portal has partnered with Trammell Crow Company, one of the largest commercial real estate developers in the United States, to catalyze the Chicago regional life sciences ecosystem at the Fulton Labs Campus and is currently investing in and supporting companies in its existing 11,000 square feet of wet and dry lab and office space at 1375 West Fulton Street. “I am thrilled to expand our operations in Fulton Labs during a very exciting time for breakthroughs in biotech,” said Patrick Flavin. “Portal’s expansion of lab and office space will accelerate our ability to invest in, house, and support the promising life sciences companies that are emerging from the region’s top tier research institutions.” About Portal Innovations Portal Innovations is a premier venture development engine that bridges scientific ideation in life sciences, medtech, and bioinformatics through commercial proof of concept by delivering crafted capital, including seed funding, specialized equipment, lab space, and management expertise to high-potential early-stage companies.

Read More


Invest Ontario Supports New Biomanufacturing Facility in Hamilton

Invest Ontario | April 01, 2022

Invest Ontario is supporting OmniaBio Inc. in launching a new biomanufacturing facility that will catalyze Ontario life sciences jobs and innovation while advancing pioneering medicine with the potential to cure, not just treat, many forms of cancer, cardiovascular diseases, Parkinson's and diabetes. OmniaBio, a Canadian cell and gene therapy contract development and manufacturing organization (CDMO), will be the anchor tenant in a new biomanufacturing campus being built in Hamilton's McMaster Innovation Park. Subject to reaching a definitive agreement, Invest Ontario will provide a loan of up to $40 million, contributing to an overall project investment of over $580 million, creating 250 jobs by 2031. Invest Ontario will also be providing non-financial support to OmniaBio, including helping the company meet its future talent needs and promoting opportunities to enhance local skills development partnerships. As a contract manufacturer, OmniaBio will support a broad range of cell and gene therapy companies – both homegrown and international – by providing process development and clinical/commercial production services in compliance with global health standards. The OmniaBio investment supports Ontario's new Life Sciences Strategy that will advance the province's leadership as a North American life sciences hub offering a collaborative ecosystem for the development, commercialization and adoption of innovative health products and services. OmniaBio is being spun out of the Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM), a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. OmniaBio will build on CCRM's existing global client base, with the project ultimately creating a six-fold increase in biomanufacturing capacity. Ontario's life sciences sector is the largest in Canada (representing more than 50 per cent of related economic activity) and comprises about 1,900 firms employing around 66,000 people.

Read More


The scope of the journal includes the research, industrial and commercial aspects of biotechnology, in areas such as: Healthcare and Pharmaceuticals; Food and Agriculture; Biofuels; Genetic Engineering and Molecular Biology; Genomics and Synthetic Biology; Nanotechnology; Environment and Biodiversity; Biocatalysis; Bioremediation; Process engineering.